Barcelona-based epigentics specialist Oryzon Genomics, SA, a clinical-stage biopharmaceutical company and a European leader in epigenetics, announced today the successful completion has completed an oversubscribed €30m capital increase through issuing 12,765,958 new shares, priced at €2.35 per share.
Yeast on the Final Frontier
Latest NewsA team led by Imperial College London has launched a miniature lab into Earth orbit to test the production of edible proteins in space with the help of yeast-based biotech.
BioFlo 320: Moving from R&D to commercial manufacturing
ProductsPrecise parameter control is the foundation for efficient bioprocessing and scale-up. However, identifying the ideal scale-up strategy can be a work-intensive and time-consuming task. Here, the BioFlo 320 bioprocess controller with its innovative Scale Up Assist and other features can help you simplifying your cell culture process and scale up to working volumes of up to 40 L.
ADC Applications Beyond Oncology
slider, Sponsored PublicationsAntibody-Drug Conjugates (ADCs) have been transformative in oncology, offering targeted cancer treatments that enhance efficacy while sparing healthy cells. However, the potential of ADCs extends well beyond cancer care. From autoimmune diseases to metabolic disorders, advancements in ADC technology are paving the way for breakthroughs across a range of therapeutic areas. This article explores how ADCs are redefining treatment paradigms and improving patient outcomes in diverse fields of medicine.
Discover the Dynamic Landscape of GLP-1 Drug Development
slider, Sponsored PublicationsExplore the evolving world of GLP-1 receptor agonists in Issue 42 of The Altascientist, featuring insights on their expanding applications, early-phase development, and real-world case studies.
betaSense GmbH identifies new diagnostic biomarker for Parkinson’s
Latest NewsA new biomarker for Parkinson’s disease makes it possible to recognise and treat the hereditary dopamine deficiency before the mid-brain is damaged, reports University Bochum spin-out betaSense GmbH.
Oryzon cashes in €30m
Latest NewsBarcelona-based epigentics specialist Oryzon Genomics, SA, a clinical-stage biopharmaceutical company and a European leader in epigenetics, announced today the successful completion has completed an oversubscribed €30m capital increase through issuing 12,765,958 new shares, priced at €2.35 per share.
Cytovation ASA bags additional US$6m to drive Phase II study
Latest NewsCytovation ASA has baged US$6m to advance Phase II development of its bi-specific pore-forming peptide candidate CY-101 in patients with adrenocortical carcinoma.
KKR makes US$1.22bn tender for Swedish Biotage AB
Latest NewsRWK Bidco AB, newly founded by the private equity firm KKR (Kohlberg Kravis Roberts & Co.), has identified Swedish separation specialist Biotage AB as a takeover target and submitted an official takeover offer.
Boehringer Ingelheim inks deal with Tessallate Bio
Latest NewsBoehringer Ingelheim and synthetic lethality specialist Tessellate Bio have entered into an €500m biobucks global license agreement on oral first-in-class cancer treatments.
Roche and Novartis react to US tariffs
Latest NewsDespite the World Trade Organisation’s (WTO) ban of tariffs on pharmaceuticals, US President Donald Trump has announced he would consider imposing tariffs on pharmaceutical products. In a fast reaction, Swiss pharmaceutical giants Roche and Novartis, which are heavily dependent on the US market, have announced upcoming investments in the US as a production location by 2030.